Viana Do Castelo

• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1
• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting
  2025-521797-34-00 5 2026-01-20 Diabetes Mellitus, Type 1
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 5 2025-06-15 Ulcerative colitis
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting
  2023-504724-25-00 5 2024-10-16 Primary Myelofibrosis
• An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting
  2023-504031-41-00 5 2024-03-25 ER+/HER2- Early Breast Cancer
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY) Ended recruitment
  2024-516609-22-00 5 2025-04-15 Primary Sjögren’s Disease
• Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon®) in Pancreatic Exocrine Insufficiency (PEI) due to gastrectomy. Ended recruitment
  2023-507837-18-00 6 2025-03-06 Male and female patients aged ≥ 18 to ≤ 80 after total gastrectomy.
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• Endoscopic evidence of maintenance of healing with oral NEXIUM in patients 1 to 11 years old with erosive esophagitis. Ended recruitment
  2023-505454-18-00 5 2021-11-24 Erosive Esophagitis
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or … Ended recruitment
  2023-505478-14-00 5 2019-05-09 Psoriatic Arthritis
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• ABTECT-1 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -1 Ended
  2022-500535-36-01 5 2023-06-12 Moderately to severely active ulcerative colitis
• A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine … Ended
  2024-510612-75-00 5 2022-08-31 Participants with T2D and overweight
• Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease Ended
  2024-511553-22-00 5 2018-10-05 Moderately to Severely Active Crohn's Disease

Showing 1–23 of 23 trials